英创远达制药 CASI 深 沪
已收盘 09-26 16:00:00 美东时间
1.31
-0.201
-13.30%
华盛通- 最 高1.55
- 今 开1.51
- 成交量 174.66万股
- 最 低 1.21
- 昨 收 1.511
- 总市值 2029.56万
- 52周最高 7.50
- 市盈率 静 --
- 换手率 0.01%
- 52周最低 1.0909
- 委 比 -55.68%
- 总股本 1549.28万
- 历史最高 88.92
- 量 比 63.14
- 振 幅 22.50%
- 历史最低 1.0909
- 每 手 1
- 风险率 1.55%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Indaptus Therapeutics (NASDAQ: INDP) stock moved upwards by 108.1% to $6.83 during Friday's regular session. The market value of their outstanding shares is at $3.6 million.
09-27 01:05
CASI Pharmaceuticals Strengthens Board with Industry Veteran James Huang
CASI Pharmaceuticals ( ($CASI) ) has provided an update. On September 26, 2025,...
09-26 21:47
HC Wainwright & Co. Reiterates Buy on CASI Pharmaceuticals, Maintains $4 Price Target
HC Wainwright & Co. analyst Sean Lee reiterates CASI Pharmaceuticals (NASDAQ:CASI) with a Buy and maintains $4 price target.
09-03 19:00
CASI Pharmaceuticals Faces Setback with FOLOTYN® License Expiration in China
The latest announcement is out from CASI Pharmaceuticals ( ($CASI) ). CASI Phar...
08-28 04:55
Why Dayforce Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket
Shares of Dayforce Inc (NYSE:DAY) rose sharply in pre-market trading. Bloomberg...
08-18 18:51
Cassava Reports Q2 2025 Financials Results and Provides Business Update
Cassava Sciences reported Q2 2025 results, including a net loss of $44.2 million, cash of $112.4 million, and plans to advance simufilam for TSC-related epilepsy. The company appointed new neuroscience leaders and settled securities litigation with a $31.25 million loss contingency.
08-14 11:30
Century Casinos, Inc. Announces Second Quarter 2025 Results
Company Initiates Strategic Review Process to Enhance Shareholder Value. COLORADO SPRINGS, Colo., Aug. 7, 2025 /PRNewswire/ -- Century Casinos, Inc. (the "Company", "we", "us", or "our") (Na...
08-07 18:00
Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer
Cassava Sciences, Inc. has appointed Dr. Joseph Hulihan as Chief Medical Officer. With over 25 years of experience in developing therapies for epilepsy and other neurological disorders, Dr. Hulihan will focus on advancing simufilam, a potential treatment for Tuberous Sclerosis Complex (TSC)-related epilepsy. The clinical study for simufilam is expected to begin in H1 2026. Dr. Hulihan previously served as CMO at Marinus Pharmaceuticals and held s...
08-07 11:30
CASI Pharmaceuticals shares are trading higher after the company announced FDA clearance for CID-103.
CASI Pharmaceuticals shares are trading higher after the company announced FDA ...
08-04 23:39
CASI Pharmaceuticals Appoints David Cory as CEO to Drive CID-103 Program
CASI Pharmaceuticals ( ($CASI) ) has issued an announcement. On July 21, 2025, ...
07-22 18:28
